CorMedix Acquires Seven Drug Products, Expands Revenue to $305-335mln by 2025.

• CorMedix acquires seven innovative drug products and pipeline expansion. • Expected to be near-term accretive to EPS with double-digit accretion in 2026. • Annual run-rate synergies expected to be $35-$45 million. • Pro forma 2025 combined revenues estimated at $305-$335 million. • Advances CorMedix's strategy for a specialty pharmaceutical business. • Expands platform for additional products and growth.

CorMedix Inc. (Nasdaq: CRMD) has announced the acquisition of seven innovative drug products and pipeline expansion, which is expected to be near-term accretive to earnings per share (EPS) with double-digit accretion in 2026. The company expects annual run-rate synergies of $35-$45 million, with pro forma 2025 combined revenues estimated at $305-$335 million. This acquisition advances CorMedix's strategy for a specialty pharmaceutical business and expands its platform for additional products and growth.

The acquisition, which includes Melinta Therapeutics LLC, aims to bolster CorMedix's portfolio and enhance its capabilities in the biopharmaceutical sector. The company reported strong financial results for the second quarter and six months ended June 30, 2025, with net revenue of $39.7 million and net income of $19.8 million, respectively [1].

CorMedix's management team will host a conference call and webcast today, August 7, 2025, at 8:30 a.m. Eastern Time, to discuss the acquisition and recent corporate developments. The call details and dial-in information are as follows: Domestic: 1-844-676-2922, International: 1-412-634-6840, Webcast: Webcast Link.

References:
[1] https://www.globenewswire.com/news-release/2025/08/07/3129077/0/en/Cormedix-Inc-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html